• Wondering whether Eli Lilly's current share price still makes sense after a strong run, or if you might be paying too much for future expectations? This article focuses squarely on what the valuation signals are really saying.
• Eli Lilly recently closed at US$1,015.75, with the stock up 2.9% over the past week and 9.3% over the last month, while year to date it is down 6.0% and up 43.0% over the past year, with a very large gain over five years.
• Recent headlines around Eli Lilly have highlighted growing interest in its drug pipeline and the broader enthusiasm for large pharmaceutical stocks. This has kept the stock firmly on the radar of many investors. At the same time, commentary has increasingly focused on whether expectations already embedded in the price are stretching traditional valuation measures.
• Eli Lilly currently holds a valuation score of 3 out of 6 on Simply Wall St. The next sections will walk through how different valuation methods assess that score and hint at an even richer way to think about valuation that comes at the end of this article.

Approach 1: Eli Lilly Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of a company's future cash flows, then discounts them back to a single value in today's terms. It is essentially asking what those future dollars are worth right now.

For Eli Lilly, the model used here is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in $. The company’s last twelve month free cash flow is about $8.6b. Analysts provide explicit forecasts for the next few years, and Simply Wall St extends those projections out further, with free cash flow for 2030 estimated at $46.8b. The ten year path between today and 2035 blends analyst inputs and extrapolated figures.

When all those future cash flows are discounted back using this framework, the estimated intrinsic value comes out at about $1,404 per share, compared with the recent share price of $1,015.75. That implies the stock trades at roughly a 27.7% discount to this DCF estimate. Under these cash flow assumptions, the model indicates that the shares may be inexpensive relative to this valuation.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Eli Lilly is undervalued by 27.7%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Approach 2: Eli Lilly Price vs Earnings

For a profitable company like Eli Lilly, the P/E ratio is a useful way to see what you are paying for each dollar of earnings. It quickly links the share price to the business’s ability to generate profit.

What counts as a “normal” P/E depends on how fast earnings are expected to grow and how risky those earnings appear. Higher expected growth and lower perceived risk often support a higher P/E, while slower growth or higher risk usually point to a lower one.

Eli Lilly currently trades on a P/E of 35.8x, compared with an average of 23.3x for peers and 15.3x for the broader Pharmaceuticals industry. Simply Wall St’s Fair Ratio for Eli Lilly is 37.2x, which is its proprietary estimate of what the P/E could be given factors like earnings growth, profit margin, industry, market cap and risk profile.

The Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for company specific traits rather than relying on broad group averages. With Eli Lilly’s actual P/E slightly below the 37.2x Fair Ratio, the stock screens as modestly undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Eli Lilly Narrative

Earlier the article mentioned that there is an even better way to understand valuation. This is where Narratives come in: a simple tool on Simply Wall St’s Community page that lets you connect your view of Eli Lilly’s story to a set of revenue, earnings and margin assumptions. You can then link that forecast to a Fair Value and compare it with today’s share price to decide if the stock looks attractive or stretched. Everything updates automatically as fresh earnings or news arrives, so you can see, for example, one investor arguing Eli Lilly is worth around US$1,200 per share while another pins Fair Value closer to US$900, and decide which story, and which set of numbers, you find more convincing.

For Eli Lilly however we will make it really easy for you with previews of two leading Eli Lilly Narratives:

Think of these as two clear stories anchored in numbers, showing how different assumptions about GLP 1 demand, pricing and competition can lead to very different views on what the stock is worth.

Fair value: US$1,189.18

Implied discount to this narrative fair value: about 14.6% based on the recent US$1,015.75 share price

Revenue growth assumption: 20%

• Focuses on GLP 1 drugs as the key driver, with Mounjaro and Zepbound forecasts that point to very large tirzepatide sales supported by patent protection out to around 2036.
• Assumes production capacity is the main bottleneck, not demand, with new plants expected to support higher volumes and potentially lower unit costs over time.
• Builds a case for revenue growth over the next 3 to 5 years based on low current GLP 1 penetration, improving insurance coverage and a US$1,200 per share valuation using a 9% discount rate.

Fair value: US$899.73

Implied premium to this narrative fair value: about 12.9% based on the recent US$1,015.75 share price

Revenue growth assumption: 12.33%

• Emphasises risks from potential US drug pricing reforms, pressure to align US and European pricing and the effect this could have on high profile obesity and diabetes medicines.
• Highlights reliance on a small group of GLP 1 and diabetes products, with concerns about future competition, patent expiry, safety headlines and higher R&D costs affecting margins.
• Uses a lower fair value of US$899.73 that reflects a required P/E of about 24x on 2029 earnings, and notes that current pricing already reflects demanding assumptions about revenue, margins and long term obesity market size.

Taken together, these Narratives show how much the story you consider about GLP 1 demand, pricing pressure and execution can influence your view of what Eli Lilly is worth, and where the current US$1,015.75 share price sits between those ranges.

If you want to see more detail or build your own view around different growth, margin and fair value inputs, See what the community is saying about Eli Lilly.

Do you think there's more to the story for Eli Lilly? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.